These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 17686159

  • 1. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI.
    Endocrinology; 2003 Nov; 144(11):5105-17. PubMed ID: 12960029
    [Abstract] [Full Text] [Related]

  • 6. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI.
    Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
    [Abstract] [Full Text] [Related]

  • 7. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.
    Int J Cancer; 2010 Jan 15; 126(2):545-62. PubMed ID: 19609946
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Relation between c-erbB1, c-erbB2, MAPK expression and resistance to tamoxifen in breast cancer cells in vitro].
    Zhang QY, Zhao WH, Kang XM.
    Zhonghua Zhong Liu Za Zhi; 2006 Nov 15; 28(11):826-30. PubMed ID: 17416003
    [Abstract] [Full Text] [Related]

  • 12. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM, Kim J, Holst MR, Knudsen SL, Grandal MV, van Deurs B.
    Cell Signal; 2012 Jan 15; 24(1):296-301. PubMed ID: 21951604
    [Abstract] [Full Text] [Related]

  • 13. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R.
    Cytometry; 2001 Aug 01; 44(4):338-48. PubMed ID: 11500850
    [Abstract] [Full Text] [Related]

  • 14. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.
    Clin Cancer Res; 2006 Jul 01; 12(13):4103-11. PubMed ID: 16818711
    [Abstract] [Full Text] [Related]

  • 15. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI.
    Breast Cancer Res Treat; 2006 Mar 01; 96(2):131-46. PubMed ID: 16261397
    [Abstract] [Full Text] [Related]

  • 16. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
    Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA.
    Endocr Relat Cancer; 2008 Dec 01; 15(4):985-1002. PubMed ID: 18824559
    [Abstract] [Full Text] [Related]

  • 17. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
    Shien T, Doihara H, Hara H, Takahashi H, Yoshitomi S, Taira N, Ishibe Y, Teramoto J, Aoe M, Shimizu N.
    Breast Cancer; 2004 Dec 01; 11(4):367-73. PubMed ID: 15604992
    [Abstract] [Full Text] [Related]

  • 18. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
    Awasthi S, Hamburger AW.
    J Cell Physiol; 2014 Nov 01; 229(11):1831-41. PubMed ID: 24692179
    [Abstract] [Full Text] [Related]

  • 19. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
    Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR, Condeelis JS, Hynes NE, Segall JE.
    Oncogene; 2012 Feb 09; 31(6):706-15. PubMed ID: 21725367
    [Abstract] [Full Text] [Related]

  • 20. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Feb 09; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.